Pharmacosmos supports the IPVS 2010

December 22, 2009

The International Pig Veterinary Society Congress is an important venue for gathering leading swine veterinarians and researchers globally to discuss best-practices in pig breeding and handling.

For the second time in four years, Pharmacosmos is proud to be industrial supporter of the IPVS Congress held in Vancouver, Canada, July 18 - July 21, 2010.

Mogens Toftegaard Petersen, Regional Veterinary Business Manager at Pharmacosmos, comments: "Timely and effective iron injection for prevention of iron deficiency in piglets is a well-established practice in modern pig production management. Today, we know that injectable iron therapy in faster growing piglets can be optimized and lead to improved production performance. IPVS is an important venue where new developments in production management are established. By supporting the IPVS 2010, we are pleased to contribute to bringing awareness to best-practices that help pig-breeders worldwide optimize their production management."

Last time Pharmacosmos supported the IPVS was in 2006, when the congress was held in Copenhagen, Denmark.

For more information about the IPVS 2010, please visit

About Uniferon

Uniferon is a modern improved iron hydrogenated dextran based on a natural formula, which is approved for global use:

Uniferon is manufactured without the use of any organic solvents or cyanide, thus, avoiding trace residues of these impurities. Pharmacosmos manufactures iron dextran of high quality and unique purity for customers worldwide. Uniferon is the only injectable iron brand for piglets approved in the EU, the US and Asia.

About Pharmacosmos

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.